⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274089 | 0.65 | — | — | |
| SCHEMBL2886583 | 0.60 | — | — | |
| SCHEMBL2040935 | 0.60 | — | — | |
| SCHEMBL4932940 | 0.55 | — | — | |
| SCHEMBL620794 | 0.55 | — | — | |
| SCHEMBL3130973 | 0.55 | — | — | |
| SCHEMBL794478 | 0.55 | — | — | |
| SCHEMBL5821772 | 0.55 | — | — | |
| SCHEMBL22440696 | 0.54 | — | — | |
| SCHEMBL20943499 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211252-B2 | Furazane derivatives, preparation thereof and energetic compositions containing them | EURENCO (FR) | 2012-07-03 | — | — | US | claimed |
| US-20100132856-A1 | FURAZANE DERIVATIVES, PREPARATION THEREOF AND ENERGETIC COMPOSITIONS CONTAINING THEM | SNPE MATERIAUX ENERGETIQUES (FR) | 2010-06-03 | — | — | US | claimed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | claimed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | claimed |
| US-5155216-A | Nucleic acids labeled with a chemiluminescent acridine ester | AMOCO CORPORATION (US) | 1992-10-13 | — | — | US | claimed |
| JP-6329560-A | — | — | None | — | — | JP | disclosed |
| US-8211252-B2 | Furazane derivatives, preparation thereof and energetic compositions containing them | EURENCO (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20100132856-A1 | FURAZANE DERIVATIVES, PREPARATION THEREOF AND ENERGETIC COMPOSITIONS CONTAINING THEM | SNPE MATERIAUX ENERGETIQUES (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2125796-A1 | FURAZANE DERIVATIVES, PREPARATION THEREOF AND ENERGETIC COMPOSITIONS CONTAINING THEM | SNPE Matériaux Energétiques (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008102092-A1 | FURAZANE DERIVATIVES, PREPARATION THEREOF AND ENERGETIC COMPOSITIONS CONTAINING THEM | SNPE MATERIAUX ENERGETIQUES (FR) | 2008-08-28 | — | — | WO | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| JP-H06329560-A | METHOD FOR INTRODUCING IMIDE GROUP INTO HETEROCYCLIC COMPOUND | TOKYO YATSUKA UNIV | 1994-11-29 | — | — | JP | disclosed |
| US-5155216-A | Nucleic acids labeled with a chemiluminescent acridine ester | AMOCO CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |